the discovery and development of liraglutide and semaglutide Frontiers Liraglutide and Semaglutide Market Share

There are other important secondary outcomes, including the change in logMAR visual acuity, the development of center-involved diabetic macular edema (CI-DME) and the development of retinopathy, macular edema or vitreous hemorrhage requiring treatment

Orforglipron received an FDA Commissioner's National Priority Voucher in late 2025, which expedites review

Military providers may recommend alternative GLP-1 agents or temporary suspension during peak training cycles or deployments

It was found that the LAAM GSH-CQDs penetrated tumor cells, such as A549 and HeLa cells, and were mainly located in the cytoplasm, showing red fluorescence (Fig

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes (TRIUMPH-2)